🇺🇸 FDA
Pipeline program

Tolebrutinib

EFC16645

Phase 3 small_molecule completed

Quick answer

Tolebrutinib for Non-relapsing Secondary Progressive Multiple Sclerosis is a Phase 3 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pasteur
Indication
Non-relapsing Secondary Progressive Multiple Sclerosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials